Vitestro today launched its Aletta autonomous robotic phlebotomy device (ARPD) that performs automated blood draws.

This phlebotomy training programme in adult venepuncture will incorporate academic learning in addition to practical application. The period of training lasts up to 3 months, leading to an assessment ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Vitestro has unveiled Aletta, claimed to be the “world's first” Autonomous Robotic Phlebotomy Device (ARPD), designed for ...

Hastings Public Schools Foundation, Mary Lanning Healthcare Foundation, and Central Community College have all agreed to ...

DocGo, a mobile health services provider, has acquired PTI Health, a company specialising in mobile lab collection and phlebotomy services in the mid-Atlantic region. This move aims to address the ...

Vitestro, a pioneer in medical robotics, proudly reveals the name of its autonomous blood drawing device: Aletta™, the first ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Officials with the Office of Workforce Development and Community Education at Missouri State University-West Plains (MSU-WP) ...

Vitestro has introduced Aletta, and they claim it's the world's first autonomous robotic phlebotomy device, marking a ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...